Standardized Procedures for Patients with Dysplasia and Other Diseases of the Cervix, Vulva, and Vagina at a Certified Dysplasia Unit Prior to the Introduction of the Organized Cervical Cancer Screening Program

Abstract

Introduction Gynecologic dysplasia units and dysplasia consultations are obliged to offer diagnosis and treatment in accordance with the guidelines. The organization of the consultation process, management of patient appointments, diagnosis, and treatment algorithms are heterogeneous. The legislation arising from the new Federal Joint Committee decision, dated 22 November 2018, concerning the organized cervical cancer screening program has been in force since 1 January 2020. In this article we provide an overview of the existing structures and interdisciplinary cooperation of specialized dysplasia units incorporated in certified gynecologic cancer center.

Materials and Methods We carried out a retrospective database search of data collected prospectively from 1 July 2014 to 31 December 2019 at the dysplasia unit at the Department of Gynecology and Obstetrics, Erlangen University Hospital, which was the first dysplasia unit to be certified in 2014.

Results A total of 5594 patients presented at the unit, and 16061 colposcopic, vulvoscopic, and anoscopic examinations were performed. Approximately 4100 examinations of the cervix, vagina, vulva, and anus are carried out each year, 1600 of these were exclusively cervix colposcopies. A total of 12197 cytology results were assessed, as well as 4850 histology results, and 8193 high-risk HPV tests. The quality indicators required by the dysplasia unit for annual recertification were met each year.

Conclusion Certified dysplasia units and consultations form the central component in the algorithm for further investigating abnormal screening results; but they are also the first point of contact for a large number of patients with acute or chronic complaints in the genital region.

Keywords

dysplasia unit - dysplasia - Pap smear - HPV - colposcopy

Publikationsverlauf

Eingereicht: 06. April 2022

Angenommen nach Revision: 25. August 2022

Artikel online veröffentlicht:
15. August 2023

• References/Literatur

• 1 OnkoZert GmbH. Suchportal der zertifizierten Zentren. oncoMAP. Zugriff am 01. November 2020 unter: http://www.oncomap.de/index.php
• 2 Arbeitsgemeinschaft Zervixpathologie und Kolposkopie e.V. (AG CPC). Das Portal der: Dysplasiesprechstunden. Zugriff am 30. Oktober 2022 unter: https://www.dysplasieportal.de/dysplasieeinheiten/ Zugriff am 30. Oktober 2022 unter: https://www.dysplasieportal.de/dysplasiesprechstunden/
• 3 Beckmann MW, Quaas J, Bischofberger A. et al. Establishment of the Certification System “Gynaecological Dysplasia” in Germany. Geburtshilfe Frauenheilkd 2014; 74: 860-867
• 4 Beckmann MW, Stübs FA, Koch MC. et al. Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy. Geburtshilfe Frauenheilkd 2022; 82: 139-180
• 5 Fehm T, Stübs FA, Koch MC. et al. Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities. Geburtshilfe Frauenheilkd 2022; 82: 181-205
• 6 Hoyer H, Mehlhorn G, Scheungraber C. et al. Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance. Cancers (Basel) 2021; 13: 3309
• 7 Jesinghaus M, Strehl J, Boxberg M. et al. Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix. J Pathol Clin Res 2018; 4: 93-102
• 8 Schulmeyer CE, Stübs F, Gass P. et al. Correlation between referral cytology and in-house colposcopy-guided cytology for detecting early cervical neoplasia. Arch Gynecol Obstet 2020; 301: 263-271
• 9 Stuebs FA, Gass P, Dietl AK. et al. Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix. Arch Gynecol Obstet 2021; 304: 751-758
• 10 Stuebs FA, Koch MC, Mehlhorn G. et al. Accuracy of colposcopic findings in detecting vaginal intraepithelial neoplasia: a retrospective study. Arch Gynecol Obstet 2020; 301: 769-777
• 11 Stuebs FA, Mehlhorn G, Gass P. et al. Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia. Gynecol Oncol 2020; 157: 463-468
• 12 Stuebs FA, Schulmeyer CE, Mehlhorn G. et al. Accuracy of colposcopy-directed biopsy in detecting early cervical neoplasia: a retrospective study. Arch Gynecol Obstet 2019; 299: 525-532
• 13 Gemeinsamer Bundesausschuss. Pressemitteilung Nr. 38/2016. Eckpunkte für zukünftiges Screening auf Gebärmutterhalskrebs geändert. 2016 Zugriff am 02. Februar 2022 unter: https://www.g-ba.de/downloads/34-215-641/38-2016-09-15_KFE-RL_Eckpunkte%20Zervix.pdf
• 14 Kühn W, Lélle RJ. Die klinische Bedeutung der neuen histologischen WHO-Nomenklatur (2014) der Präkanzerosen der Cervix uteri und Vagina. gyn 2015; 20: 48-54
• 15 AG-CPC. Münchner Nomenklatur III für die gynäkologische Zytodiagnostik der Zervix. 2017 Zugriff am 02. Februar 2022 unter: http://www.ag-cpc.de/pages/muenchen-iii.php
• 16 Kühn W, Gieseking F. Die aktuellen Empfehlungen der AG-CPC zur Kolposkopie 2015. gyn 2015; 20: 25-47
• 17 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses für organisierte Krebsfrüherkennungsprogramme oKFE-Richtlinie/oKFE-RL 2021. 01.07.2021 Zugriff am 01. Oktober 2022 unter: https://www.g-ba.de/downloads/62–492–2605/oKFE-RL-2021–07–01-iK-2022–01–01.pdf
• 18 OnkoZert. Erhebungsbogen für Gynäkologische Krebszentren der Deutschen Krebsgesellschaft. 13.07.2020 Zugriff am 01. Oktober 2022 unter: https://www.onkozert.de/wordpress/wp-content/uploads/2019/09/eb_gz-G1_190911.pdf
• 19 DIMDI (Deutsches Institut für Medizinische Dokumentation und Information). ICD-10-GM Version 2020. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10. Revision. 2020 Zugriff am 02. Februar 2022 unter: https://www.dimdi.de/static/de/klassifikationen/icd/icd-10-gm/kode-suche/htmlgm2020/
• 20 DIMDI (Deutsches Institut für Medizinische Dokumentation und Information). Operationen- und Prozedurenschlüssel Version 2019 mit Aktualisierungen bis zum 3. Dezember 2018. 2019 Zugriff am 02. Februar 2022 unter: https://www.dimdi.de/static/de/klassifikationen/ops/kode-suche/opshtml2019/
• 21 Hillemanns P, Friese K, Dannecker C. et al. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 2 on Triage, Treatment and Follow-up. Geburtshilfe Frauenheilkd 2019; 79: 160-176
• 22 Hillemanns P, Friese K, Dannecker C. et al. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia. Geburtshilfe Frauenheilkd 2019; 79: 148-159
• 23 Schnürch HG, Ackermann S, Alt CD. et al. Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015. Geburtshilfe Frauenheilkd 2016; 76: 1035-1049
• 24 Schnürch HG, Ackermann S, Alt-Radtke CD. et al. Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). Geburtshilfe Frauenheilkd 2019; 79: 1060-1078
• 25 Arbeitsgemeinschaft Zervixpathologie und Kolposkopie e.V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. Zervixkarzinomscreening 2020. 2020 Zugriff am 21. Mai 2022 unter: https://www.ag-cpc.de/kolposkopiediplom-und-zertifizierung/zervixkarzinomscreening-2020/
• 26 Thiel FC, Scharl A, Hildebrandt T. et al. Financing of certified centers: a willingness-to-pay analysis. Arch Gynecol Obstet 2013; 287: 495-509
• 27 TOMBOLA Group. Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ 2009; 339: b2549
• 28 TOMBOLA Group. Biopsy and selective recall compared with immediate large loop excision in management of women with low grade abnormal cervical cytology referred for colposcopy: multicentre randomised controlled trial. BMJ 2009; 339: b2548
• 29 Cotton SC, Sharp L, Little J. et al. Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): Trial design. Contemp Clin Trials 2006; 27: 449-471
• 30 Lee SS, Collins RJ, Pun TC. et al. Conservative treatment of low grade squamous intraepithelial lesions (LSIL) of the cervix. Int J Gynaecol Obstet 1998; 60: 35-40
• 31 Quaas J, Reich O, Frey Tirri B. et al. Explanation and Use of the Colposcopy Terminology of the IFCPC (International Federation for Cervical Pathology and Colposcopy) Rio 2011. Geburtshilfe Frauenheilkd 2013; 73: 904-907
• 32 O’Connor M, O’Brien K, Waller J. et al. Physical after-effects of colposcopy and related procedures, and their inter-relationship with psychological distress: a longitudinal survey. BJOG 2017; 124: 1402-1410
• 33 Prignano F, Campolmi P, Bonan P. et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther 2009; 22 (Suppl. 01) S8-S15
• 34 Salvatore S, Nappi RE, Zerbinati N. et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014; 17: 363-369
• 35 Lee A, Lim A, Fischer G. Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus. Australas J Dermatol 2016; 57: 39-43